Summit: A Cautious Bet Backed By Anti-VEGF And Insider Buying [Seeking Alpha]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Seeking Alpha
SMMT's Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism, with the potential to outperform the benchmarks. While there's a lot of uncertainty regarding sales and even more regarding earnings, valuation suggests significant upside if the company captures just 4% market share by 2033. There are 5 risks and caveats, which include therapy efficacy and toxicity to be studied, financing, competition, and high product concentration. Jitendra Jadhav/iStock via Getty Images Thesis I'm rating Summit Therapeutics ( SMMT ) as a "cautious buy" due to the promising combination of anti-PD-1 plus anti-VEGF. If the company manages to reach just 4% of market share in 2033, it implies a potential 15% annualized CAGR upside. This This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the st
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.MarketBeat
- Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- 2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 10/20/25 - Beat
SMMT
Sec Filings
- 1/12/26 - Form 4
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- SMMT's page on the SEC website